TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Zivo Bioscience ( (ZIVO) ).
On July 8, 2025, Zivo Bioscience, Inc. issued a Bridge Promissory Note worth $250,000 and a warrant to purchase shares as part of a new convertible debt offering aimed at raising $2,000,000. This financial maneuver is designed to provide flexibility in financing, allowing conversion of debt to equity under certain conditions, which could impact the company’s capital structure and appeal to investors by offering potential equity participation.
Spark’s Take on ZIVO Stock
According to Spark, TipRanks’ AI Analyst, ZIVO is a Underperform.
Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company’s negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.
To see Spark’s full report on ZIVO stock, click here.
More about Zivo Bioscience
Zivo Bioscience, Inc. operates in the biotechnology industry, focusing on developing and commercializing health and wellness products derived from its proprietary algal culture technology.
Average Trading Volume: 1,012
Technical Sentiment Signal: Sell
Current Market Cap: $51.94M
For a thorough assessment of ZIVO stock, go to TipRanks’ Stock Analysis page.